18 Nov 2025
22:01 CET |
ARGENX SE |
argenx Announces Results of Extraordinary General Meeting of Shareholders
|
20103010 Biotechnology |
Other subject |
30 Oct 2025
07:00 CET |
ARGENX SE |
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
|
20103010 Biotechnology |
Other subject |
29 Oct 2025
16:00 CET |
ARGENX SE |
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
|
20103010 Biotechnology |
Other subject |
23 Oct 2025
07:00 CEST |
ARGENX SE |
argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
|
20103010 Biotechnology |
Other subject |
15 Oct 2025
07:00 CEST |
ARGENX SE |
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
|
20103010 Biotechnology |
Other subject |
03 Oct 2025
22:01 CEST |
ARGENX SE |
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
|
20103010 Biotechnology |
Other subject |
28 Aug 2025
07:00 CEST |
ARGENX SE |
argenx to Present at Upcoming Investor Conferences
|
20103010 Biotechnology |
Other subject |
25 Aug 2025
07:00 CEST |
ARGENX SE |
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
|
20103010 Biotechnology |
Other subject |
19 Aug 2025
07:00 CEST |
ARGENX SE |
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
|
20103010 Biotechnology |
Other subject |
12 Aug 2025
12:45 CEST |
ARGENX SE |
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
|
20103010 Biotechnology |
Other subject |
31 Jul 2025
07:00 CEST |
ARGENX SE |
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
|
20103010 Biotechnology |
Other subject |
24 Jul 2025
07:00 CEST |
ARGENX SE |
argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025
|
20103010 Biotechnology |
Other subject |
30 Jun 2025
07:00 CEST |
ARGENX SE |
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
|
20103010 Biotechnology |
Other subject |
20 Jun 2025
19:00 CEST |
ARGENX SE |
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
|
20103010 Biotechnology |
Other subject |
11 Jun 2025
00:01 CEST |
ARGENX SE |
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
|
20103010 Biotechnology |
Other subject |
03 Jun 2025
07:00 CEST |
ARGENX SE |
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
|
20103010 Biotechnology |
Other subject |
28 May 2025
22:01 CEST |
ARGENX SE |
argenx Announces Results of Annual General Meeting of Shareholders
|
20103010 Biotechnology |
Other subject |
08 May 2025
07:00 CEST |
ARGENX SE |
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
|
20103010 Biotechnology |
Other subject |
06 May 2025
07:00 CEST |
ARGENX SE |
argenx to Present at BofA Securities 2025 Health Care Conference
|
20103010 Biotechnology |
Other subject |
01 May 2025
07:00 CEST |
ARGENX SE |
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
|
20103010 Biotechnology |
Other subject |
28 Apr 2025
07:00 CEST |
ARGENX SE |
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
20103010 Biotechnology |
Other subject |
11 Apr 2025
22:01 CEST |
ARGENX SE |
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
|
20103010 Biotechnology |
Other subject |
10 Apr 2025
23:47 CEST |
ARGENX SE |
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
|
20103010 Biotechnology |
Other subject |
08 Apr 2025
07:00 CEST |
ARGENX SE |
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
|
20103010 Biotechnology |
Other subject |
07 Mar 2025
07:00 CET |
ARGENX SE |
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
|
20103010 Biotechnology |
Other subject |
27 Feb 2025
07:00 CET |
ARGENX SE |
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
|
20103010 Biotechnology |
Other subject |
25 Feb 2025
07:00 CET |
ARGENX SE |
argenx to Present at TD Cowen 45th Annual Healthcare Conference
|
20103010 Biotechnology |
Other subject |
20 Feb 2025
07:00 CET |
ARGENX SE |
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
|
20103010 Biotechnology |
Other subject |
13 Jan 2025
07:00 CET |
ARGENX SE |
argenx Highlights 2025 Strategic Priorities
|
20103010 Biotechnology |
Other subject |
06 Jan 2025
07:00 CET |
ARGENX SE |
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
|
20103010 Biotechnology |
Other subject |
27 Dec 2024
07:00 CET |
ARGENX SE |
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
|
20103010 Biotechnology |
Other subject |
26 Nov 2024
07:00 CET |
ARGENX SE |
argenx to Present at Upcoming Investor Conferences
|
20103010 Biotechnology |
Other subject |
20 Nov 2024
07:00 CET |
ARGENX SE |
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
|
20103010 Biotechnology |
Other subject |
11 Nov 2024
13:30 CET |
ARGENX SE |
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
|
20103010 Biotechnology |
Other subject |
05 Nov 2024
07:00 CET |
ARGENX SE |
argenx to Participate at Upcoming Investor Conferences
|
20103010 Biotechnology |
Other subject |
31 Oct 2024
07:00 CET |
ARGENX SE |
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
|
20103010 Biotechnology |
Other subject |
24 Oct 2024
07:00 CEST |
ARGENX SE |
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
|
20103010 Biotechnology |
Other subject |
15 Oct 2024
07:00 CEST |
ARGENX SE |
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
|
20103010 Biotechnology |
Other subject |
19 Sep 2024
07:00 CEST |
ARGENX SE |
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
|
20103010 Biotechnology |
Other subject |
28 Aug 2024
07:00 CEST |
ARGENX SE |
argenx to Present at Upcoming Investor Conferences
|
20103010 Biotechnology |
Other subject |
25 Jul 2024
07:00 CEST |
ARGENX SE |
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
|
20103010 Biotechnology |
Other subject |
18 Jul 2024
07:00 CEST |
ARGENX SE |
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
|
20103010 Biotechnology |
Other subject |
16 Jul 2024
06:30 CEST |
ARGENX SE |
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
|
20103010 Biotechnology |
Other subject |
25 Jun 2024
22:30 CEST |
ARGENX SE |
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
|
20103010 Biotechnology |
Other subject |
21 Jun 2024
22:50 CEST |
ARGENX SE |
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
|
20103010 Biotechnology |
Other subject |
17 Jun 2024
07:00 CEST |
ARGENX SE |
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
|
20103010 Biotechnology |
Other subject |
04 Jun 2024
07:00 CEST |
ARGENX SE |
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
|
20103010 Biotechnology |
Other subject |
09 May 2024
07:00 CEST |
ARGENX SE |
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
|
20103010 Biotechnology |
Other subject |
07 May 2024
23:30 CEST |
ARGENX SE |
argenx announces results of Annual General Meeting of Shareholders
|
20103010 Biotechnology |
Other subject |
07 May 2024
07:00 CEST |
ARGENX SE |
argenx to Present at BofA Securities 2024 Health Care Conference
|
20103010 Biotechnology |
Other subject |